ViGenCell

At a glance

ViGenCell filed 30 disclosures in the last 12 months, including 7 5% holder and 6 insider. The most recent key filing was on Mar 31.

Revenue for 2025 was ₩22.7M, down 91.9% on 2024. It made an operating loss of ₩17.1B. Debt was 24% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩899.9M and operating loss of ₩5.4B.

The 2025 annual report lists 43 employees with an average tenure of 4.1 years and average pay of ₩86.2M. Its 8 directors and auditors were paid ₩80.8M each on average. It paid no cash dividend for 2025. 가은글로벌(주) and related parties held 21.51% at year end.

From the 2025 annual report

Staff: 43 (16 men, 27 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩6.6B. Directors and auditors: 8, paid ₩646.3M in total.

No cash dividend was paid for 2025.

Largest shareholder

가은글로벌(주) holds 10.68%; with 2 related parties the group holds 21.51% of common shares at year end (from 23.06% at the start of the year).

Auditor: 이정회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary